Clinical Pathway Discloses One Surgeon's $425 Habit

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 6
Volume 5
Issue 6

PHILADELPHIA--When practice guidelines or pathways take financial considerations into account, they may be termed clinical financial pathways (CFPs). This technique was developed by Kent Giles, MPPM, vice president of development at PhyMatrix, a physician management company headquartered in West Palm Beach, Fla, and is currently being utilized by PhyMatrix to reduce unnecessary medical costs.

PHILADELPHIA--When practice guidelines or pathways take financialconsiderations into account, they may be termed clinical financialpathways (CFPs). This technique was developed by Kent Giles, MPPM,vice president of development at PhyMatrix, a physician managementcompany headquartered in West Palm Beach, Fla, and is currentlybeing utilized by PhyMatrix to reduce unnecessary medical costs.

Developing CFPs involves seven steps, Mr. Giles said at the Associationof Cancer Executives meeting (see also page 20): Select a diseaseprocess, form a knowledgeable team, clarify the current stateof medical knowledge, develop the pathway, assign costs to eachprocess, implement the pathway, and monitor the results.

During development of the prostate CFP, he said, the team foundthat one urologist was using three surgical trays per radicalprostatectomy to access the three instruments he needed, sincethe hospital routinely placed only one of these instruments onthe surgical tray.

This practice, which added $425 in unnecessary costs for extrasterilization and wasted anesthesiologist and surgeon time, waseliminated with implementation of the CFP, and the patient's timeunder anesthesia was reduced by 30 minutes, ie, a quality enhancement.

Recent Videos
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
Related Content